Application of FLIC model to predict adverse events onset in neuroendocrine tumors treated with PRRT.
Aged
Antineoplastic Agents
/ administration & dosage
Drug-Related Side Effects and Adverse Reactions
/ diagnosis
Female
Humans
Lutetium
/ chemistry
Male
Middle Aged
Models, Theoretical
Neoplasm Grading
Neoplasm Staging
Neuroendocrine Tumors
/ complications
Prognosis
Radioisotopes
/ chemistry
Radiopharmaceuticals
/ administration & dosage
Renal Insufficiency
/ diagnosis
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
30 09 2021
30 09 2021
Historique:
received:
05
07
2021
accepted:
16
09
2021
entrez:
1
10
2021
pubmed:
2
10
2021
medline:
30
12
2021
Statut:
epublish
Résumé
To develop predictive models of side effect occurrence in GEPNET treated with PRRT. Metastatic GEPNETs patients treated in our centre with PRRT (177Lu-Oxodotreotide) from 2019 to 2020 were considered. Haematological, liver and renal toxicities were collected and graded according to CTCAE v5. Patients were grouped according with ECOG-PS, number of metastatic sites, previous treatment lines and therapies received before PRRT. A FLIC model with backward selection was used to detect the most relevant predictors. A subsampling approach was implemented to assess variable selection stability and model performance. Sixty-seven patients (31 males, 36 females, mean age 63) treated with PRRT were considered and followed up for 30 weeks from the beginning of the therapy. They were treated with PRRT as third or further lines in 34.3% of cases. All the patients showed at least one G1-G2, meanwhile G3-G5 were rare events. No renal G3-G4 were reported. Line of PRRT administration, age, gender and ECOG-PS were the main predictors of haematological, liver and renal CTCAE. The model performance, expressed by AUC, was > 65% for anaemia, creatinine and eGFR. The application of FLIC model can be useful to improve GEPNET decision-making, allowing clinicians to identify the better therapeutic sequence to avoid PRRT-related adverse events, on the basis of patient characteristics and previous treatment lines.
Identifiants
pubmed: 34593940
doi: 10.1038/s41598-021-99048-8
pii: 10.1038/s41598-021-99048-8
pmc: PMC8484673
doi:
Substances chimiques
Antineoplastic Agents
0
Radioisotopes
0
Radiopharmaceuticals
0
Lutetium
5H0DOZ21UJ
Lutetium-177
BRH40Y9V1Q
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
19490Commentaires et corrections
Type : ErratumIn
Informations de copyright
© 2021. The Author(s).
Références
Dasari, A. et al. Trends in the incidence, prevalence and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 3, 1335–1342 (2017).
doi: 10.1001/jamaoncol.2017.0589
Fraenkel, M. et al. Incidence of gastro-enteropancreatic neuroendocrine tumours: A systematic review of the literature. Endocr. Relat. Cancer. 21, R153–R163 (2014).
doi: 10.1530/ERC-13-0125
Leoncini, E. et al. Increased incidence trend of low-grade and high-grade neuroendocrine neoplasms. Endocrine 58, 368–379 (2017).
doi: 10.1007/s12020-017-1273-x
Huguet, I. et al. Changes in the epidemiology of neuroendocrine tumours. Neuroendocrinology 104, 105–111 (2017).
doi: 10.1159/000441897
WHO Classification of Tumours Editorial Board; Digestive System Tumours, WHO Classification of Tumours. 5th ed. IARC Press. 2019.
Lawrence, B. et al. The epidemiology of gastroenteropancreatic neuroendocrine tumors. Endocrinol. Metab. Clin. N. Am. 40(1), 1–18. https://doi.org/10.1016/j.ecl.2010.12.005 (2011).
doi: 10.1016/j.ecl.2010.12.005
Norlén, O. et al. Long-term results of surgery for small intestinal neuroendocrine tumors at a tertiary referral center. World J. Surg. 36(6), 1419–1431. https://doi.org/10.1007/s00268-011-1296-z (2012).
doi: 10.1007/s00268-011-1296-z
Ahmed, A. et al. Midgut neuroendocrine tumours with liver metastasis: Results of the UKINETS study. Endocr. Relat. Cancer 16, 885–894 (2009).
doi: 10.1677/ERC-09-0042
Strosberg, J. et al. Phase 3 trial of 177Lu-dotatate for midgut neuroendocrine tumors. N. Engl. J. Med. 376(2), 125–135. https://doi.org/10.1056/NEJMoa1607427 (2017).
doi: 10.1056/NEJMoa1607427
Fazio, N. et al. Everolimus in advanced, progressive, well-differentiated, non-functional neuroendocrine tumors: RADIANT-4 lung subgroup analysis. Cancer Sci. 109(1), 174–181. https://doi.org/10.1111/cas.13427 (2018).
doi: 10.1111/cas.13427
Yao, J. C. et al. Everolimus for advanced pancreatic neuroendocrine tumors. N. Engl. J. Med. 364, 514–523. https://doi.org/10.1056/NEJMoa1009290) (2011).
doi: 10.1056/NEJMoa1009290)
Sahu, A. et al. CAPTEM in metastatic well-differentiated intermediate to high grade neuroendocrine tumors: A single centre experience. J. Oncol. 2019, 9032753. https://doi.org/10.1155/2019/9032753 (2019).
doi: 10.1155/2019/9032753
De Mestier, L. et al. Comparison of temozolomide-capecitabine to 5-fluorouracile-dacarbazine in 247 patients with advanced digestive neuroendocrine tumors using propensity score analyses. Neuroendocrinology 108(4), 343–353. https://doi.org/10.1159/000498887 (2019).
doi: 10.1159/000498887
Nicolini, S. et al. Combined use of 177Lu-DOTATATE and metronomic capecitabine (Lu-X) in FDG-positive gastro-entero-pancreatic neuroendocrine tumors. Eur. J. Nucl. Med. Mol. Imaging. https://doi.org/10.1007/s00259-021-05236-z (2021).
doi: 10.1007/s00259-021-05236-z
Brabander, T. et al. Long-term efficacy, survival, and safety of [177Lu-DOTA0, Tyr3]octreotate in patients with gastroenteropancreatic and bronchial neuroendocrine tumors. Clin. Cancer Res. 23(16), 4617–4624. https://doi.org/10.1158/1078-0432 (2017).
doi: 10.1158/1078-0432
Efficacy and safety of 177Lu-edotreotide PRRT in GEP-NET patients—Full text view—ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03049189 .
Study to evaluate the efficacy and safety of Lutathera in patients with grade 2 and grade 3 advanced GEP-NET—Full text view—ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03972488 .
Antitumor efficacy of peptide receptor radionuclide therapy with 177lutetium-octreotate randomized vs sunitinib in unresectable progressive well-differentiated neuroendocrine pancreatic tumor: First randomized phase II—Full text view—ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02230176 .
Pavel, M. Gastroenteropancreatic neuroendocrine neoplasms: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 31(7), 844–860. https://doi.org/10.1016/j.annonc.2020.03.304 (2020).
doi: 10.1016/j.annonc.2020.03.304
Lutathera | European Medicines Agency. https://www.ema.europa.eu/en/medicines/human/EPAR/lutathera .
AGENZIA ITALIANA DEL FARMACO | DETERMINA 11 marzo 2019. https://www.aifa.gov.it/documents/20142/847786/Determina_501-2019_Lutathera.pdf .
Rudisile, S. et al. Salvage PRRT with 177Lu-DOTA-octreotate in extensively pre-treated patients with metastatic neuroendocrine tumor (NET): Dosimetry, toxicity, efficacy, and survival. BMC Cancer 19, 788. https://doi.org/10.1186/s12885-019-6000-y (2019).
doi: 10.1186/s12885-019-6000-y
Panzuto, F. et al. Real-world study of everolimus in advanced progressive neuroendocrine tumors. Oncologist 19, 966–974 (2014).
doi: 10.1634/theoncologist.2014-0037
Heckert, J. M. et al. Abnormal pre-treatment liver function tests are associated with discontinuation of peptide receptor radionuclide therapy in a U.S.-based Neuroendocrine Tumor Cohort. Oncologist 25, 572–578 (2020).
doi: 10.1634/theoncologist.2019-0743
Bodei, L. et al. Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: The value and limitations of clinical factors. EJNMMI 42(1), 5–19. https://doi.org/10.1007/s00259-014-2893-5 (2015).
doi: 10.1007/s00259-014-2893-5
Faggiano, A. et al. Therapeutic sequences in patients with grade 1–2 neuroendocrine tumors (NET): An observational multicenter study from the ELIOS group. Endocrine 66(2), 417–424 (2019).
doi: 10.1007/s12020-019-01894-0
Chen, L. et al. 177 Lu-DOTATATE in older patients with metastatic neuroendocrine tumours: Safety, efficacy and health-related quality of life. Eur. J. Nucl. Med. Mol. Imaging https://doi.org/10.1007/s00259-021-05332-0 (2021).
doi: 10.1007/s00259-021-05332-0
Mansournia, M. A., Geroldinger, A., Greenland, S. & Heinze, G. Separation in logistic regression: Causes, consequences and control. Am. J. Epidemiol. 187(4), 864–870 (2018).
doi: 10.1093/aje/kwx299
Safety of Lanreotide 120 mg ATG in combination with metformin in patients with progressive advanced well-differentiated gastro-intestinal (gi) or lung carcinoids: A pilot, one-arm, open-label, prospective study—Full Text View—ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02823691 .
Firth, D. Bias reduction of maximum likelihood estimates. Biometrika 80, 27 (1993).
doi: 10.1093/biomet/80.1.27
Puhr, R., Heinze, G., Nold, M., Lusa, L. & Geroldinger, A. Firth’s logistic regression with rare events: Accurate effect estimated and predictions?. Stat. Med. 36(14), 2302–2317 (2017).
De Bin, R., Janitza, S., Sauerbrei, W. & Boulesteix, A. L. Subsampling versus bootstrapping in resampling-based model selection for multivariable regression. Biometrics 72(1), 272–280. https://doi.org/10.1111/biom.12381 (2016).
doi: 10.1111/biom.12381
R: A language and environment for statistical computing. R Core Team, R Foundation for Statistical Computing, Vienna, Austria, 2019. https://www.R-project.org/ .
https://rdocumentation.org/packages/logistf/versions/1.24 .
Kwekkeboom, D. J. et al. Treatment With the radiolabeled somatostatin analog [177Lu-DOTA0, Tyr3]Octreotate: Toxicity, efficacy, and survival. J. Clin. Oncol. 26(13), 2124–2130 (2008).
doi: 10.1200/JCO.2007.15.2553
Fröss-Baron, K. et al. 177Lu-DOTATATE therapy of advanced pancreatic neuroendocrine tumors heavily pretreated with chemotherapy: Analysis of outcome, safety, and their determinants. Neuroendocrinology 111(4), 330–343 (2021).
doi: 10.1159/000506746
Medaer, E. et al. Influence of pretreatment with everolimus or sunitinib on the subacute hematotoxicity of 177Lu-DOTATATE PRRT. Acta Oncol. 59(6), 644–651. https://doi.org/10.1080/0284186X.2020.1723161 (2020).
doi: 10.1080/0284186X.2020.1723161
Bergsma, H. et al. Subacute haematotoxicity after PRRT with (177)Lu-DOTA-octreotate: Prognostic factors, incidence and course. Eur. J. Nucl. Med. Mol. Imaging. 43(3), 453–463 (2016).
doi: 10.1007/s00259-015-3193-4
Qazi, J. Z. et al. Predicting major bleeding among hospitalized patients using oral anticoagulants for atrial fibrillation after discharge. PLoS ONE 16(3), e0246691 (2021).
doi: 10.1371/journal.pone.0246691
Mongoldi, S. et al. Ten-year experience with standardized non-operating room anaesthesia with Sevoflurane for MRI in children affected by neuropsychiatric disorders. BMC Anesthesiol. 19, 235 (2019).
doi: 10.1186/s12871-019-0897-1
Zeng, C. et al. Bias correction of risk estimates in vaccine safety studies with rare adverse events using a self-controlled case series design. Am. J. Epidemiol. 178(12), 1750–1759 (2013).
doi: 10.1093/aje/kwt211